| Annual Financials | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
Revenue  | 2,337 | 2,665 | 2,960 | 3,416 | 3,792 | 4,208 | 4,391 | 4,997 | 5,503 | 6,097 | 6,524 |
| Expenses | 1,977 | 2,250 | 2,505 | 2,774 | 3,074 | 3,337 | 3,389 | 3,832 | 4,143 | 4,396 | 4,648 |
| EBITDA | 360 | 415 | 455 | 642 | 718 | 871 | 1,002 | 1,165 | 1,360 | 1,701 | 1,876 |
| Operating Profit % | 13 % | 14 % | 14 % | 16 % | 16 % | 18 % | 21 % | 22 % | 23 % | 25 % | 26 % |
| Depreciation | 15 | 14 | 16 | 16 | 17 | 60 | 58 | 66 | 70 | 71 | 72 |
| Interest | 1 | 3 | 2 | 4 | 2 | 9 | 18 | 19 | 16 | 12 | 10 |
| Profit Before Tax | 344 | 398 | 437 | 622 | 699 | 803 | 926 | 1,080 | 1,274 | 1,618 | 1,794 |
| Tax | 115 | 143 | 160 | 220 | 249 | 210 | 235 | 281 | 324 | 417 | 451 |
| Net Profit | 229 | 255 | 277 | 401 | 450 | 593 | 691 | 799 | 949 | 1,201 | 1,335 |
| EPS in ₹ | 107.75 | 120.12 | 130.19 | 188.81 | 211.93 | 279.04 | 325.04 | 375.87 | 446.80 | 565.30 | 628.00 |
Abbott
29,641.10
+533.05
(1.83%)
Market Cap
62,985.27 Cr
EPS
565.30
PE Ratio
46.40
Dividend Yield
1.41 %
Industry
Healthcare52 Week High
31,898.95
52 Week Low
25,200.00
PB Ratio
17.58
Debt to Equity
0.03
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from5 analysts
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,687.55 | #1 4,04,899.77 | 33.61 | #1 49,887.20 | 12.06 | #1 9,648 | 13.77 | 47.60 | |
5,589.30 | 1,48,378.35 | 69.15 | 8,184.00 | 0.89 | 1,600 | #1 64.53 | 47.92 | |
1,463.05 | 1,18,158.10 | 22.92 | 26,520.70 | 14.17 | 4,155 | 47.38 | 50.89 | |
3,129.00 | 1,05,899.58 | 56.83 | 10,785.70 | 11.59 | 1,656 | 13.54 | 45.29 | |
2,350.50 | 96,976.58 | 46.77 | 10,615.60 | 19.57 | 1,942 | -16.38 | 48.68 | |
1,109.50 | 92,582.82 | #1 17.01 | 28,905.40 | 12.36 | 5,578 | 1.69 | 40.66 | |
1,969.25 | 89,904.33 | 30.58 | 20,141.50 | #1 19.94 | 1,936 | 38.82 | 46.62 | |
868.85 | 87,426.64 | 18.74 | 19,831.50 | 13.82 | 3,831 | 29.92 | 44.56 | |
29,641.10 | #9 62,985.27 | #7 46.40 | #10 6,097.20 | #9 10.80 | #10 1,201 | #5 16.01 | 48.36 | |
1,082.45 | 62,868.87 | 17.41 | 29,559.20 | 17.55 | 3,169 | -10.04 | 41.61 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
10.80 %
Net Income Growth
26.52 %
Cash Flow Change
35.75 %
ROE
9.07 %
ROCE
9.92 %
EBITDA Margin (Avg.)
12.91 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 1,374 | 1,617 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,194 |
| Fixed Assets | 96 | 109 | 110 | 81 | 105 | 270 | 251 | 271 | 237 | 225 |
| Current Assets | 1,226 | 1,451 | 1,893 | 2,266 | 2,761 | 3,205 | 3,487 | 3,853 | 3,025 | 3,246 |
| Capital Work in Progress | 4 | 3 | 6 | 2 | 1 | 2 | 1 | 1 | 4 | 10 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1,274 | 1,505 | 1,950 | 2,333 | 2,835 | 3,275 | 3,589 | 3,953 | 4,315 | 4,958 |
| Total Liabilities | 1,374 | 1,617 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,194 |
| Current Liabilities | 397 | 382 | 632 | 668 | 857 | 891 | 1,031 | 1,203 | 1,206 | 1,343 |
| Non Current Liabilities | 39 | 39 | 47 | 55 | 75 | 224 | 207 | 201 | 161 | 152 |
| Total Equity | 938 | 1,196 | 1,387 | 1,693 | 2,009 | 2,432 | 2,602 | 2,820 | 3,189 | 3,699 |
| Reserve & Surplus | 916 | 1,174 | 1,366 | 1,672 | 1,987 | 2,410 | 2,581 | 2,799 | 3,167 | 3,678 |
| Share Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | -30 | 91 | 62 | -165 | 99 | 8 | 73 | -86 | 107 | 52 |
| Investing Activities | -187 | -77 | -155 | -215 | -257 | -401 | -72 | -396 | -148 | -416 |
| Operating Activities | 215 | 249 | 307 | 153 | 499 | 626 | 727 | 948 | 893 | 1,213 |
| Financing Activities | -58 | -80 | -90 | -102 | -143 | -217 | -582 | -637 | -639 | -745 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
| Promoter | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.18 % | 0.18 % | 0.18 % | 0.16 % | 0.16 % |
| DIIs | 4.60 % | 5.80 % | 4.30 % | 4.20 % | 4.96 % | 5.24 % | 7.73 % | 8.39 % | 8.62 % | 8.67 % | 8.71 % | 8.74 % | 8.91 % | 8.81 % | 8.99 % | 9.01 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 16.15 % | 15.83 % | 15.60 % | 15.81 % | 15.15 % | 14.72 % | 14.60 % | 14.25 % | 14.07 % | 13.95 % | 13.89 % | 13.97 % | 13.80 % | 13.86 % | 13.65 % | 13.59 % |
| Others | 4.26 % | 3.38 % | 5.11 % | 5.01 % | 4.91 % | 5.06 % | 2.68 % | 2.37 % | 2.32 % | 2.39 % | 2.42 % | 2.13 % | 2.12 % | 2.16 % | 2.21 % | 2.25 % |
| No of Share Holders | 0 | 84,478 | 75,540 | 73,417 | 83,236 | 90,567 | 82,113 | 83,526 | 72,086 | 69,582 | 68,885 | 72,252 | 69,382 | 71,588 | 69,449 | 67,892 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 40 | 55 | 65 | 250 | 275 | 275 | 325 | 410 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.73 | 0.75 | 0.42 | 1.67 | 1.55 | 1.26 | 1.2 | 1.33 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Change in ManagementApr 01, 2025
Apr 01, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 01, 2025
Apr 01, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMar 26, 2025
Mar 26, 2025Closure of Trading WindowMar 25, 2025
Mar 25, 2025Rumour verification - Regulation 30(11)Mar 06, 2025
Mar 06, 2025Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Feb 27, 2025
Feb 27, 2025Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Feb 27, 2025
Feb 27, 2025Announcement under Regulation 30 (LODR)-Change in ManagementFeb 20, 2025
Feb 20, 2025Integrated Filing (Financial)Feb 06, 2025
Feb 06, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 06, 2025
Feb 06, 2025Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024Feb 05, 2025
Feb 05, 2025Board Meeting Outcome for Outcome Of Board MeetingFeb 05, 2025
Feb 05, 2025Announcement under Regulation 30 (LODR)-Change in ManagementFeb 03, 2025
Feb 03, 2025Board Meeting Intimation for Intimation Of Board Meeting Scheduled On February 5 2025 For Considering Unaudited Financial Results For Quarter And Nine Months Ended December 31 2024.Jan 28, 2025
Jan 28, 2025Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015.Jan 23, 2025
Jan 23, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJan 21, 2025
Jan 21, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJan 16, 2025
Jan 16, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 09, 2025
Jan 09, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJan 03, 2025
Jan 03, 2025Closure of Trading WindowDec 23, 2024
Dec 23, 2024Announcement under Regulation 30 (LODR)-Resignation of DirectorDec 16, 2024
Dec 16, 2024Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)Dec 16, 2024
Dec 16, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 13, 2024
Dec 13, 2024Abbott Launches 14 Valent Pneumococcal Conjugate Vaccine (PCV-14) That Offers Broadest Protection For Children Against Pneumococcal Bacterial Infections.Nov 28, 2024
Nov 28, 2024Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements), Regulations, 2015.Nov 28, 2024
Nov 28, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 14, 2024
Nov 14, 2024Intimation Under Regulation 30 Of The Securities And Exchange Board Of India ( Listing Obligations And Disclosure Requirements), Regulations, 2015.Nov 14, 2024
Nov 14, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 12, 2024
Nov 12, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 08, 2024
Nov 08, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 08, 2024
Nov 08, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 07, 2024
Nov 07, 2024Related Party Transaction Statement For The Half Year Ended September 30, 2024Nov 07, 2024
Nov 07, 2024Announcement under Regulation 30 (LODR)-Change in DirectorateNov 07, 2024
Nov 07, 2024Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024Nov 07, 2024
Nov 07, 2024Board Meeting Outcome for Outcome Of Board MeetingNov 07, 2024
Nov 07, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 05, 2024
Nov 05, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateOct 31, 2024
Oct 31, 2024Board Meeting Intimation for Intimation Under Regulation 29(1)(A) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.Oct 28, 2024
Oct 28, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateOct 23, 2024
Oct 23, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateOct 19, 2024
Oct 19, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateOct 18, 2024
Oct 18, 2024Announcement under Regulation 30 (LODR)-Change in ManagementOct 18, 2024
Oct 18, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateOct 15, 2024
Oct 15, 2024Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 11, 2024
Oct 11, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateOct 09, 2024
Oct 09, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateOct 01, 2024
Oct 01, 2024Closure of Trading WindowSep 26, 2024
Sep 26, 2024Announcement Under Regulation 30 (LODR)Sep 19, 2024
Sep 19, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateSep 13, 2024
Sep 13, 2024Technical Indicators
RSI(14)
Neutral 48.36
ATR(14)
Less Volatile 878.54
STOCH(9,6)
Neutral 38.00
STOCH RSI(14)
Neutral 23.48
MACD(12,26)
Bearish -178.84
ADX(14)
Weak Trend 19.12
UO(9)
Bearish 49.64
ROC(12)
Downtrend And Accelerating -4.61
WillR(14)
Neutral -44.67
About Abbott
Abbott India Ltd is a leading multinational pharmaceutical company in India. It operates an owned manufacturing facility in Goa and works with various independent contract manufacturers across the country. The company sells its products primarily within India through independent distributors. Abbott India provides pharmaceutical products and solutions across various therapeutic areas including Women's Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, Vaccines, and Consumer Health. The company is structured into four divisions: Primary Care, Specialty Care-Methabolics and Urology, Specialty Care-Neuroscience, and Hospital Care. Abbott India manufactures and markets a wide range of products including Brufen, Prothiaden, Thyronorm, Leptos, Digene, Cremaffin, Influvac, and many others. The company has expanded its product portfolio through launches, acquisitions, and partnerships over the years. Abbott India is engaged in research and development, conducting clinical studies and publishing in medical journals. The company has also been recognized for innovation in the pharmaceutical industry.
Website
Chairperson NameMunir Shaikh
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
